Following the release of the results, Bell Potter Securities affirmed its $16 target for Mesoblast shares – which is close to three times the current trading price, which has recently hovered around $6.
In a research note, Bell Potter said the plan to conduct a phase II RA trial “adds another high-value, un-partnered programme to Mesoblast, given the high prevalence of RA globally, the US$12 billion global market for existing RA drugs, and the drawbacks of those drugs.”
Mesoblast is also investigating the use of MPCs to treat Type 2 diabetes, and entered the phase II trial stage for this project at the start of the year.
bell potter
Add MSB (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
99.0¢ |
Change
0.010(1.02%) |
Mkt cap ! $1.130B | |||
| Open | High | Low | Value | Volume |
| 99.5¢ | $1.02 | 98.5¢ | $5.507M | 5.501M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 9996 | 99.0¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 99.5¢ | 18069 | 3 |
View Market Depth
| Last trade - 16.10pm 28/06/2024 (20 minute delay) ? |
| MSB (ASX) Chart |